A Utrnscript generated by the distal part of the Duchenne Muscular Dystrophy (DMD) gene was initially detected In cells where the full size 14-kilobase (kb) messenger RNA is not found at a si nt level. This transcript, '-4.5 kb long, corresponds to the cysteine-rich and carboxylterminal domains of dystrophin. It begins with a novel 80-to 100-nucleotide exon containing an ATG start site for a new coding sequence of 17 nucleotldes in-frame with the consecutive dystrophin cDNA sequence from exon 63. This result suggests
terminal domains of dystrophin. It begins with a novel 80-to 100-nucleotide exon containing an ATG start site for a new coding sequence of 17 nucleotldes in-frame with the consecutive dystrophin cDNA sequence from exon 63. This result suggests the existence of a third promoter that would be localized about 8 kilobases upstream from exon 63 of the DMD gene. The distal transcript is widely distributed but is absent in adult skeletal and myometrial muscle. It is much more abundant in fetal tissues. With an antibody directed against the dystrophin carboxyl terminus, the protein corresponding to this transcript was detected as a 70-to 75-kDa entity on Western blots. It was found in all tissues analyzed except in skeletal muscle. It was not found in lymphoblastold cells from a Duchenne patient with a complete deletion of the dystrophin gene. The role and subcellular localization of this protein is not known. It may explain extramuscular symptoms exhibited by some Duchenne patients.
The huge X-linked DMD gene, which is abnormal in Duchenne and Becker muscular dystrophies (1, 2) , is controlled by different promoters in different tissues (3, 4) . A promoter active in skeletal muscle, heart, and smooth muscle and a neuron-specific promoter (5, 6) , which is located 90 kilobase pairs (kbp) upstream of the muscle-specific promoter (7) , control the production oftwo 14-kilobase (kb) mRNA species (8) that is translated into 427-kDa proteins (9) differing in their N-terminal ends. In addition, several forms generated by alternative splicing, some of them being tissue-specific or developmentally regulated, have been detected (3, 10, 11) . Most of them involve the 3' coding part of the transcripts.
In this paper, we report the characterization and expression analysis of a newly discovered transcript of the DMD gene, probably similar to the species recently reported by Bar et al. (12) . This mRNA, referred to as the "distal transcript," is about 4.5 kb long and shares with the dystrophin mRNA those exons that are located downstream of exon 62. Thus, it encodes the last two domains of the protein-i.e., the cysteine rich and C-terminal domains. Its 5' end consists of a new first exon spliced to the dystrophin exon 63 and located between exons 62 and 63 of the DMD gene. This alternative first exon contains a consensus ATG translation initiation codon in phase with the dystrophin gene sequence. The open reading frame codes for a 70-to 75-kDa protein that is detected in several tissues. Transcripts containing the alternative first exon are widely distributed in adult and fetal tissues and cell lines, but are absent from adult skeletal muscle and myometrium.
MATERIAL AND METHODS RNA Extraction. Total RNA was extracted from different cell lines and frozen tissues by the method of Chirgwin et al. (13) . The amount of RNA used for reverse transcription and amplification reactions (cDNA PCR) was determined by spectrophotometry and corrected by computerized image analysis (Vilber Lourmat, Marne la Valled, France) after loading on an agarose electrophoresis gel stained with ethidium bromide.
Quantitative cDNA PCR. PCR was performed as described in detail by Chelly et al. (10, 14) . The internal standard used here was the L-pyruvate kinase mRNA amplified from rat liver.
Nuclease S1 Protection Assay. This assay was performed with a single-stranded, quasi-end-labeled probe as described by Cognet et al. (15) .
RNA Blot-Hybridization Analysis. After electrophoresis in a 20 mM methylmercury(II)/1% (wt/vol) agarose gel, Northern blot analysis was carried out as described by Bayley et al. (16) . Anchored PCR. The 5' sequence ofthe distal transcript was obtained by anchored PCR as described (17) . cDNA synthesis was performed by primer extension of an oligonucleotide complementary to nucleotides 10,055-10,075. The cDNA was then 3'-tailed by terminal deoxynucleotidyltransferase (Boehringer Mannheim), under conditions designed to add about 15-30 dGMP residues. PCR amplification was performed with a 3' complementary oligonucleotide spanning nucleotides 9885-9904 of the dystrophin sequence. The 5' PCR primers and conditions have been described by Loh et al. (17) . The PCR products were size-fractionated by 1% (wt/vol) agarose gel electrophoresis, electroeluted, digested with Not I restriction enzyme, and then cloned in the Not I/HincII sites of Bluescript KSII(-) plasmid (Stratagene).
Mapping and Cloning of a Genomic Fragment Including the Alternative Exon. Cosmids, isolated by using 63.1 dystrophin cDNA clone (position 7880 to the end) (18) as a hybridization probe on Imperial Cancer Research Fund flow-sorted chromosome X cosmid filter (19) , were used to map and clone the genomic region of interest. Analysis of these cosmids by hybridization with the oligonucleotide probe allowed isolation of two overlapping cosmids (DMD3'-8 and DMD3 '-12) that contained the sequence specific to the distal transcript. To define the position of the alternative exon, the cosmids were restriction-mapped with Sac I, Sac 11, HindIII, and EcoRI. Southern blots were hybridized with probes derived from the exon corresponding to the 12-kb HindIII genomic 7506 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 7507 fragment detected by the 63.1 dystrophin cDNA prob the alternative exon, respectively (see Results). To seqi the genomic fragment, HindIII fragments ofcosmid DM were cloned into HindIII-cut Bluescript KSII(-) pla Recombinant colonies hybridizing with a distal trans specific oligonucleotide probe were further analyzes sequenced.
Cell Culture. Cultures of mouse brain neurons and glial cells were prepared and maintained as described 21).
Protein Analysis. Immunoblotting was performed c tially as described by Nicholson et al. (22) with the foll4 modifications. The samples were fractionated on 1-mm polyacrylamide gel by using a 3% stacking gel and a 5 gradient-resolving gel. Mandra-1 is a primary mono( antibody against the end of the C-terminal domain ol trophin (amino acid residues 3558-3684) (G.E.M., u1 lished data). spliced species corresponds to the 32-nucle tion found by Bar et al. (12) in one liver ci To confirm the presence ofa transcript in 1 performed a nuclease S1 protection assay ment B (Fig. 1 Upper) as a probe. Thi protected not only in muscle but also in lyr not shown).
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(Upper) Total RNA was extracted from lymphoblastoid cell lines of a normal subject (1) .? -Im this exon revealed a C+G-rich region without TATA box or A+T-rich element (Fig. 5 Right) .
Determination of the Sequence of the 5' End of the Rat Distal Transcript. Several couples of primers were used to perform cDNA PCR under low-stringency hybridization conditions with total rat liver RNA as a template. We then directly sequenced the band that hybridized with an internal oligonucleotide probe after a step of gel purification. This rat sequence, shown in Fig. 3 , is highly homologous to the human sequence downstream from the ATG codon except for one amino acid-a glutamine residue in the human sequence that is replaced by a histidine in the rat. In contrast, the sequence upstream from the ATG is not conserved.
Detection of a 70-to 75-kDa Protein Product with a Monoclonal Antibody Directed Against the C-Terminal Domain of Dystrophin. The new transcript described above should code for a protein containing the cysteine-rich and the C-terminal domain of dystrophin. Using a monoclonal antibody directed against the end of this region (Mandra-1), we showed in
Western blot experiments that a protein of 70-75 kDa is present in lymphoblastoid cells of a normal subject but is absent from patient MJ's cells (Fig. 6 ). This protein is present in brain and in cultures of brain astroglial and neuronal cells but is absent in leg skeletal muscle (Fig. 6) . It is also present in liver and Hep G2 cells (data not shown). This protein appears sometimes as a doublet, suggesting the presence of isoforms. Antibodies directed against the spectrin-like or N-terminal domains did not detect this dystrophin gene product (data not shown). DISCUSSION Using cDNA PCR with primers in the distal part of the dystrophin gene, we unexpectedly found significant amounts of transcript in nonmuscle cells. Since this result was obtained after 15 cycles of amplification, it cannot correspond to illegitimate transcripts that are not detectable at this number of cycles (24) . Bar et al. (12) have reported that nonmuscle tissues express a dystrophin distal transcript that shares with the dystrophin mRNAs the sequences encoding the last two protein domains. We confirm these results and demonstrate that, in addition, this transcript differs qualitatively from the dystrophin mRNAs by a unique 5' sequence transcribed from an additional exon located between exons 62 and 63 of the dystrophin gene. This additional exon is 80-100 nucleotides long and is precisely spliced with exon 63. It contains a putative translation initiation codon that is in good agreement with the Kozak consensus sequence [GC-CAMA instead of GCCAIGG (23)] and is in phase with the dystrophin reading frame. This ATG codon and flanking nucleotides are well conserved in rat (ACCATGA) as is the downstream coding sequence. In contrast, the sequence upstream from the ATG initiator is not homologous in human and rat, as is often observed for 5' untranslated regions of a given mRNA in different species. The length of the transcript detected by Northern blot analysis of lymphoblast RNAs is about 4.5 kb, which could correspond to 1.8 kb of the coding dystrophin mRNA sequence-from exon 63 to the stop codon-plus the unique 5' sequence (about 0.1 kb) and the 3-kb-long 3' untranslated region. Bar et al. (12) have reported a similar mRNA species with a size of 6.5 kb. Further investigations are needed to explain this size discrepancy.
The exon that is specific to the distal transcript is localized at 8 kb preceding exon 63 of the dystrophin gene. Since it has been detected by anchored PCR, it is likdly to correspond to exon 1 of the distal messenger. Therefore; we may speculate that the 5' flanking genomic sequence constitutes a potential promoter whose main structural characteristics should be discussed in the light of its pattern of expression in various tissues. The first 104 5' flanking nucleotides (positions -78 to -182 with respect to the ATG initiator) are 83% G+C-rich, while the G+C ratio is only 64% in the transcribed sequence (nucleotides -78 to +20). In contrast, a homopyrimidinehomopurine stretch of 28 nucleotides is located upstream from the G+C-rich region between positions -248 and -276. The G+C-rich flanking region contains three putative binding sites for the Sp-1 factor or related proteins but no TATA box (see Fig. 5 Right). At positions -104 to -114 (i.e., 32 nucleotides upstream from the most proximal putative start site), we find an AGCTGTGAGCT palindrome.
All of these characteristics are compatible with the genome region that precedes the novel exon being a ubiquitous promoter whose properties are currently being investigated. Consistent adult skeletal muscle and in smooth muscle. Transcriptional interference (25) between the muscular and the distal promoter could be one ofthe mechanisms responsible for this extinction.
The translation product of the distal mRNA is expected to possess 607 amino acid residues shared with dystrophin and a 6-amino-acid-long unique N-terminal peptide with polar characteristics (Arg-Glu-Gln-Leu-Lys-Gly). Its predicted molecular weight (70 kDa) fits well with the mobility of a protein that we have observed on Western blot with a monoclonal antibody specific to the carboxyl domain. This 70-to 75-kDa protein is not recognized by antibodies directed against other dystrophin domains and is found in the same cells and tissues as those accumulating the distal transcript; it is absent in skeletal muscle and present in liver, brain, lymphoblastoid cells, and Hep G2 cells. In addition, both the distal transcript and the 70-to 75-kDa protein are absent in patients with dystrophin gene deletions involving the C-terminal domains. Therefore, the 70-to 75-kDa protein is most likely the product of the distal transcript.
The putative physiological role of the 70-to 75-kDa protein is unknown. Since it is relatively abundant in brain, where, according to Bar et al. (12) , the distal transcript is expressed at least at the same level as the dystrophin transcript, it may play a role in brain cell functions. In fact, this function could be common in glial cells and neurons. Further studies will establish whether there is a correlation between synthesis of the 70-to 75-kDa protein and the mental retardation recognized in as much as 1:3 of the Duchenne muscular dystrophy patients (26) .
Note Added in Proof. The products described in this paper are probably identical to the species recently reported by Blake et al. (27) and Lederfein et al. (28) . 
